Cortisol stimulation by recombinant interferon-α2

Joe Roosth; Richard B Pollard; S. Lori Brown; Walter J. Meyer

doi:10.1016/0165-5728(86)90037-8

Cortisol stimulation by recombinant interferon-α₂

Joe Roosth, Richard B Pollard, S. Lori Brown, Walter J. Meyer

Research output: Contribution to journal › Article › peer-review

71 Scopus citations

Abstract

Serum cortisol concentrations were determined by radioimmunoassay in cancer patients undergoing experimental therapy with recombinant interferon-α₂. Cortisol concentration rose steadily after interferon administration and was significantly different from that on control day at 8 h following intramuscular injection of interferon-α₂. Cortisol elevation was increased as weekly doses of interferon were increased (0-120 × 10⁶ units). Recent clinical trials of interferons for treatment of neurological and malignant diseases provide a compelling need to understand the actions and side effects of exogenously administered interferons.

Original language	English (US)
Pages (from-to)	311-316
Number of pages	6
Journal	Journal of Neuroimmunology
Volume	12
Issue number	4
DOIs	https://doi.org/10.1016/0165-5728(86)90037-8
State	Published - 1986
Externally published	Yes

Keywords

Cortisol stimulation
Interferon-α
recombinant
Serum
Tumor

ASJC Scopus subject areas

Immunology
Immunology and Allergy
Clinical Neurology
Neurology

Access to Document

10.1016/0165-5728(86)90037-8

Cite this

@article{c14212b554b94f05b50093934c0c55cc,

title = "Cortisol stimulation by recombinant interferon-α2 ",

abstract = "Serum cortisol concentrations were determined by radioimmunoassay in cancer patients undergoing experimental therapy with recombinant interferon-α2. Cortisol concentration rose steadily after interferon administration and was significantly different from that on control day at 8 h following intramuscular injection of interferon-α2. Cortisol elevation was increased as weekly doses of interferon were increased (0-120 × 106 units). Recent clinical trials of interferons for treatment of neurological and malignant diseases provide a compelling need to understand the actions and side effects of exogenously administered interferons.",

keywords = "Cortisol stimulation, Interferon-α, recombinant, Serum, Tumor",

author = "Joe Roosth and Pollard, {Richard B} and Brown, {S. Lori} and Meyer, {Walter J.}",

year = "1986",

doi = "10.1016/0165-5728(86)90037-8",

language = "English (US)",

volume = "12",

pages = "311--316",

journal = "Advances in Neuroimmunology",

issn = "0165-5728",

publisher = "Elsevier",

number = "4",

}

TY - JOUR

T1 - Cortisol stimulation by recombinant interferon-α2

AU - Roosth, Joe

AU - Pollard, Richard B

AU - Brown, S. Lori

AU - Meyer, Walter J.

PY - 1986

Y1 - 1986

N2 - Serum cortisol concentrations were determined by radioimmunoassay in cancer patients undergoing experimental therapy with recombinant interferon-α2. Cortisol concentration rose steadily after interferon administration and was significantly different from that on control day at 8 h following intramuscular injection of interferon-α2. Cortisol elevation was increased as weekly doses of interferon were increased (0-120 × 106 units). Recent clinical trials of interferons for treatment of neurological and malignant diseases provide a compelling need to understand the actions and side effects of exogenously administered interferons.

AB - Serum cortisol concentrations were determined by radioimmunoassay in cancer patients undergoing experimental therapy with recombinant interferon-α2. Cortisol concentration rose steadily after interferon administration and was significantly different from that on control day at 8 h following intramuscular injection of interferon-α2. Cortisol elevation was increased as weekly doses of interferon were increased (0-120 × 106 units). Recent clinical trials of interferons for treatment of neurological and malignant diseases provide a compelling need to understand the actions and side effects of exogenously administered interferons.

KW - Cortisol stimulation

KW - Interferon-α

KW - recombinant

KW - Serum

KW - Tumor

UR - http://www.scopus.com/inward/record.url?scp=0022522878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022522878&partnerID=8YFLogxK

U2 - 10.1016/0165-5728(86)90037-8

DO - 10.1016/0165-5728(86)90037-8

M3 - Article

C2 - 3760157

AN - SCOPUS:0022522878

VL - 12

SP - 311

EP - 316

JO - Advances in Neuroimmunology

JF - Advances in Neuroimmunology

SN - 0165-5728

IS - 4

ER -